Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 1,660 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Dabrafenib and/or Trametinib Rollover Study

for
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers,
Location: Toronto
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT03340506

Phase 4, Recruiting

Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)

for
Cancer
Location: New York NY
Sponsor: National Center for Research Resources (NCRR)

Sex: All

Age: 18+

Code: NCT00006199

Phase 1, Recruiting

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

for
Malignant Solid Neoplasm
Location: Marshalltown IA, Ames IA, Boone IA, Fort Dodge IA,
Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT04871542

Recruiting

Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated With Radiation

for
Cancer
Location: Dallas TX
Sponsor: University of Texas Southwestern Medical Center

Sex: All

Age: 18 - 70+

Code: NCT03617237

Recruiting
New

Keep Social Randomized Controlled Trial for Young Adults With Cancer

for
Cancer
Location: Chapel Hill NC
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 22 - 39

Code: NCT07788339

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
New

Feasibility Pilot of AYA-PARTNER

for
Cancer, Malignancies Multiple
Location: Chapel Hill NC
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 18 - 39

Code: NCT07829146

Recruiting
New

A Phase I Dose-Escalation Study of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors

for
Advanced Solid Tumor (Phase 1)
Location: Fairfax VA
Sponsor: Cugene Inc.

Sex: All

Age: 18+

Code: NCT07946302

Phase 1, Recruiting

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

for
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma,
Location: Boston MA, Philadelphia PA, Charlottesville VA,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18+

Code: NCT04104776

Phase 1, Phase 2, Recruiting

Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer

for
Cancer, Solid Tumor Cancer, Pediatric Acute Myeloid Leukemia,
Location: Chicago IL
Sponsor: Tempus AI

Sex: All

Age: 0+

Code: NCT07756034

Recruiting

Studying TAK-243 in Patients With Advanced Cancer

for
Advanced Lymphoma, Advanced Malignant Solid Neoplasm,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06223542

Phase 1, Recruiting

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

for
Locally Advanced Malignant Solid Neoplasm,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 16+

Code: NCT04879121

Phase 2, Recruiting

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

for
Anatomic Stage III Breast Cancer AJCC v8,
Location: Boston MA, St Louis MO
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07137416

Phase 1, Recruiting

PEN-866 in Patients With Advanced Solid Malignancies

for
Carcinoma, Endometrial Adenocarcinoma, Neoplasms,
Location: Philadelphia PA, Bethesda MD, Fairfax VA,
Sponsor: Tarveda Therapeutics

Sex: All

Age: 18+

Code: NCT03221400

Phase 1, Phase 2, Recruiting

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

for
Ovarian Cancer, Endometrial Cancer,
Location: Boston MA, Fairfax VA, Orlando FL, Nashville TN,
Sponsor: ArriVent BioPharma, Inc.

Sex: Female

Age: 18+

Code: NCT07755436

Phase 1, Recruiting

Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors

for
Ovarian Cancer
Location: The Bronx NY, New York NY, Fort Worth TX,
Sponsor: Xencor, Inc.

Sex: Female

Age: 18+

Code: NCT07593092

Phase 1, Recruiting

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

for
Biliary Tract Cancer, Breast Cancer, Cervical Cancer,
Location: Boston MA, Miami FL, Denver CO, Nashville TN,
Sponsor: ModeX Therapeutics, An OPKO Health Company

Sex: All

Age: 18+

Code: NCT06239194

Phase 1, Phase 2, Recruiting

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

for
Colorectal Cancer, Triple Negative Breast Cancer,
Location: New York NY, Tampa FL, Columbus OH, Atlanta GA,
Sponsor: OncXerna Theraputics, Inc.

Sex: All

Age: 18+

Code: NCT05453825

Phase 2, Recruiting

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

for
Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor,
Location: The Bronx NY, New York NY, Hackensack NJ,
Sponsor: Xencor, Inc.

Sex: All

Age: 15+

Code: NCT06276491

Phase 1, Recruiting

Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies

for
Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer,
Location: Houston TX
Sponsor: Critical Outcome Technologies Inc.

Sex: All

Age: 18+

Code: NCT02433626

Phase 1, Recruiting

Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer

for
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Location: Greenville SC
Sponsor: Oncolix, Inc.

Sex: Female

Age: 18+

Code: NCT02534922

Phase 1, Recruiting

What is ovarian cancer?

Ovarian cancer begins in or near the ovaries. About 9 in 10 cases are epithelial, and most of those are high grade serous tumors that research now shows usually start in the fallopian tubes rather than the ovary. Rarer types begin in the egg cells or in hormone producing cells. It is hard to catch early. The ovaries sit deep in the pelvis, and early symptoms like bloating, pelvic or back pain, feeling full quickly, and urinary urgency are vague and common. The most frequent sign at diagnosis is abdominal swelling from fluid, which means the cancer is already advanced.

Treatment has changed. Surgery to remove as much tumor as possible, followed by platinum chemotherapy, is still the foundation. Since 2014 PARP inhibitor pills have been used to delay recurrence in BRCA mutated and similar tumors, and testing every patient for these mutations is now standard. In 2022 the first antibody drug conjugate for ovarian cancer was approved for platinum resistant disease, with full approval in 2024. Prevention has moved too. Because most cancers start in the tubes, removing only the fallopian tubes during other pelvic surgery is being tested as a way to prevent cancer without early menopause.

Ovarian cancer shares its inherited risk genes with breast, pancreatic, and prostate cancer. Our cancer treatment guide explains how targeted therapies work.

Types of ovarian cancer clinical trials

How is ovarian cancer diagnosed and tested?

Who can participate in ovarian cancer clinical trials?

The stages of ovarian cancer, and why they matter for trials

How to enroll in an ovarian cancer clinical trial